Metabolic Disturbances Characterize Patients with Idiopathic Intracranial Hypertension
|
By LabMedica International staff writers Posted on 09 Sep 2022 |

Individuals suffering from idiopathic intracranial hypertension are distinguishable by irregularities in the distribution of metabolites that can be detected in CSF, serum, and urine.
Idiopathic intracranial hypertension (IIH) is a condition characterized by increased pressure around the brain that appears without a detectable cause. The main symptoms are headache, vision problems, ringing in the ears, and shoulder pain. Complications may include vision loss. Risk factors include being overweight or a recent increase in weight. Tetracycline may also trigger the condition. Diagnosis is based on symptoms and a high opening pressure found during a lumbar puncture with no specific cause found on a brain scan. Previous studies from investigators at the University of Birmingham (United Kingdom) demonstrated that IIH also featured metabolic disturbances.
In the current study, the investigators compared women aged 18-55 years with active IIH to a sex, age, and body mass index matched control group. IIH participants were identified from neurology and ophthalmology clinics and underwent a prospective intervention to induce disease remission through weight loss with re-evaluation at 12 months.
The investigators evaluated the metabolomic profile in CSF, serum, and urine of patients with IIH compared to control subjects and measured changes in metabolism associated with clinical markers of disease activity and treatment. Clinical assessments included lumbar puncture, headache, eye examination for papilledema, and other visual measurements. Spectra of CSF, serum, and urine metabolites were acquired utilizing proton nuclear magnetic resonance spectroscopy.
Results revealed that urea was lower in IIH (CSF and urine) and correlated with intracranial pressure and headache severity. The lactate:pyruvate ratio was increased in CSF and serum of IIH patients compared to controls and decreased at 12 months. Baseline acetate was higher in IIH, correlated with headache severity and disability and was reduced at 12 months. Ketones 3-hydroxybutyrate and acetoacetate were altered in CSF at baseline in IIH and normalized at 12 months. That these metabolic disturbances were evident in CSF, serum, and urine of IIH patients suggested a pattern of global metabolic dysregulation. Furthermore, altered ketone body metabolites became normalized following therapeutic weight loss.
Senior author Dr. Alex Sinclair, professor of neurology at the University of Birmingham said, “The experiences that patients with IIH have are significant and without being picked up can have serious consequences including sight loss. This is why this research is so important. We are identifying markers that can help to both identify a way to diagnose IIH, as well as provide a much better understanding of the root causes of the condition.
The study was published in the September 8, 2022, online edition of the journal Neurology.
Related Links:
University of Birmingham
Latest Molecular Diagnostics News
- Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples
- FDA Clears Compact Molecular COVID Test for Decentralized Care Settings
- Blood-Based DNA Analysis Method Detects Early-Stage Solid Cancers
- Combined Blood and Genetic Tests Estimate Timing of Alzheimer’s Symptom Onset
- Blood Protein Analysis Helps Interpret Uncertain Rare Disease Variants
- 40-Gene Test Validated for High-Risk Squamous Cell Carcinoma
- Blood Test Helps Clarify Prostate Cancer Risk After Elevated PSA
- Common Genetic Marker Predicts Faster Motor Decline in Parkinson’s Disease
- DPYD Genotyping Assay Supports Safer Fluoropyrimidine Chemotherapy Dosing
- Secure Cloud-Connected qPCR System Enables Remote Infectious Disease Surveillance
- Project to Develop Maternal Blood Test for Rapid Fetal Oxygen Deprivation Detection
- WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response
- FDA Clears Liquid Biopsy Test to Guide Earlier Breast Cancer Therapy Switch
- Automated System Streamlines DNA Recovery for MRD-Sensitive Testing
- New Liquid Biopsy Platform Uses Red Blood Cells to Detect Hidden Cancer Signals
- Urine Genomic Test Detects More Than Nine in Ten Suspected Bladder Cancers
Channels
Clinical Chemistry
view channel
Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection
Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more
Machine Learning Supports Targeted Screening for Elevated Lipoprotein(a)
Lipoprotein(a) is an independent, genetically determined risk factor for atherosclerotic cardiovascular disease, yet routine screening remains uncommon despite guideline recommendations, leaving many high-risk... Read more
Blood Biomarker May Help Monitor Early Response to Lecanemab in Alzheimer’s Disease
Alzheimer’s disease is a progressive neurodegenerative disorder marked by amyloid-beta and tau pathology and remains a leading cause of cognitive decline in older adults. Although lecanemab, an anti-amyloid... Read moreHematology
view channel
New Automated Hemostasis Systems Become Available Across US Laboratories
Hemostasis testing supports critical decisions in surgery, anticoagulation management, and the evaluation of bleeding and thrombotic disorders, but laboratories continue to face rising volumes and complex... Read more
Variation in AML Residual Disease Testing Prompts Push for Standardization
Acute myeloid leukemia (AML) is an aggressive blood cancer in which relapse after therapy remains a persistent challenge, making measurable residual disease (MRD) detection central to risk assessment and... Read moreImmunology
view channel
Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead
Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more
New Cellular Map May Help Predict Crohn’s Disease Course in Children
Crohn’s disease in children is a common and debilitating form of inflammatory bowel disease, marked by chronic intestinal inflammation and limited pediatric-specific treatments. Clinicians must decide... Read more
Temporal Immune Profiling Reveals How Sepsis States Change Over Time
Sepsis is a life-threatening condition in which the immune response to infection becomes dysregulated, leading to rapid organ failure and death. Although antimicrobials and organ support remain standard... Read more
Study Identifies Immune Cells That Drive Harmful Autoantibody Responses in COVID-19
Autoantibodies that mistakenly attack the body’s own tissues have been linked to severe COVID-19, Long COVID, and increased risk of autoimmune disease. However, the origins of these autoantibodies during... Read moreMicrobiology
view channelMagnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing
Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more
Infant Skin Microbiome Show Links to Later Eczema and Food Allergies
Eczema, or atopic dermatitis, and food allergies often begin in infancy and are among the earliest stages of the atopic march. Atopic dermatitis alone can affect up to 20% of children, yet objective indicators... Read more
Diagnostic Stewardship Guide Targets Testing Overuse and Hospital Cost Pressures
Hospitals face persistent pressure to improve diagnostic accuracy while reducing unnecessary testing and costs. Misordered or overused assays can complicate infection metrics, trigger penalties, and strain... Read more
Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics
Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment... Read morePathology
view channel
Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer
Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more
CAP Updates Cancer Protocols to Refine Breast Cancer Biomarker Reporting and GIST Molecular Testing
Standardized biomarker reporting and molecular profiling are central to pathology-driven cancer care, but evolving practices require laboratories to keep reporting templates current. These templates capture... Read moreTechnology
view channel
ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine
Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more
Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions
Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more
New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling
Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more
Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read moreIndustry
view channel
Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities
Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Unilabs Expands Digital Pathology Across European Network with Proscia Platform
As precision medicine expands, digital pathology platforms must connect teams, sites, diagnostic data, and artificial intelligence to accelerate routine diagnosis. Sharing expertise across laboratory networks... Read more
MGI Launches Automated Multiplex Tissue Staining and Imaging System at ECP 2026
MGI Tech Co., Ltd. (Shenzhen, China) introduced VisiOmics (PMIF-20RS), a fully automated multiplex immunofluorescence staining and imaging system, at the 38th European Congress of Pathology (ECP 2026)... Read more







